top of page

Mon, 23 May

|

Jónas Einarsson Auditorium

Internal Workshop: NGS and biomarker data

This is a closed meeting for CONNECT Partners and members of all CONNECT Working Groups to join.

This is a closed meeting for CONNECT partners and working groups only.
See other events
Internal Workshop: NGS and biomarker data
Internal Workshop: NGS and biomarker data

Time & Location

23 May 2022, 13:00 – 14:30 CEST

Jónas Einarsson Auditorium, Ullernchausseen 64-66, 0379 Oslo, Norway

About the event

Welcome to the CONNECT Workshop: “NGS and biomarker data: how to build a system meeting the current and future needs of the different stakeholders?”

Host: CONNECT Working Group 4. WG4 invites all CONNECT Partners and members of all Working Groups to join. This will be a closed meeting for the CONNECT Consortium only.

Date: May 23rd, 2022, 13:00h - 14:30h plus networking afterwards and the opportunity to join the WG1 hosted seminar “Digital Pathology and AI” from 15:00h (same venue)

Venue: Jonas Einarsson Auditorium, Oslo Cancer Cluster Innovation Park, 1st Floor, Ullernchausseen 64 – 66. Link to join digitally will be added and shared beforehand.

AGENDA (Workshop will be in NORWEGIAN!)

13:00 – 13:05 Welcome and Introduction

WG Leads CONNECT WG 4

13:05 – 13:20 Storage, use and access of NGS Data in InPreD and IMPRESS

Representatives from InPreD

13:20 – 13:50 National PM Initiatives: a “geography lesson” introducing the landscape, processes, and international collaboration

  • Developing the concept for the National Genome Center

           Torunn Berge, Helse Sør-Øst RHF and Trine Rounge, Cancer Registry of Norway

  • Sharing genomic data in Norway and in the European 1+ million genomes – ethical and legal aspects

           Grethe Foss, Norwegian Directorate of Health

13:50 – 14:00 Industry Partner Perspective and INSPIRE-BIO proposal

Gry Festervoll and CONNECT Industry Partners

14:00 – 14:30 Discussion & Idea exchange

  • How to build a system that will meet the future needs of the various stakeholders (patients, clinicians, National Tumor Board, regulators, payors, and Industry)?
  • Can an INSPIRE-BIO like project be a relevant pilot? How should such a pilot look like? Which questions should be addressed to generate valuable insights and learning for Genome Center and Cancer Registry´s future set-up?

Share this event

bottom of page